Fizazi, et al. ARAMIS: Efficacy and safety of darolutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC). ASCO-GU 2019, abstract 140.
Regionale lymfeklierbestraling achterwege laten na respons op neoadjuvante chemotherapie?
sep 2025 | Borstkanker, Radiotherapie